Figure 1: Graphical illustration of the main findings from Pfeiffer et al., Cancer Research, 2022. The SH2 domain-containing tyrosine phosphatase 2 (SHP2) is a ubiquitously expressed non-receptor ...

Receptor tyrosine kinases (RTKs) are pivotal in both normal cellular functions and cancer progression, activating critical signaling pathways. In cancer therapy, targeted therapies using monoclonal ...

In 2015, researchers at UC San Francisco found a structure inside of tumor cells that biologists had never seen before. Even more surprising, a closer examination of the structure revealed that it ...

The new study can help understanding diseases stemming from the abnormal functions of the human receptor tyrosine kinases, RTKs. Much of the cell-to-cell communication is facilitated in humans by 58 ...

The deregulation of receptor tyrosine kinases (RTKs) has been implicated in nearly all forms of human cancer. As such, RTKs are the subject of major ongoing efforts to develop targeted cancer ...

Researchers have mapped interactions among all human membrane RTKs and PTPs, providing clues how these proteins work in normal cells and how they can go wrong in cancer. In 2011, Igor Stagljar, a ...

Population pharmacokinetics (popPK) and exposure-response (ER) analyses bridge J-ALEX to the global population with an alectinib (ALC) 600mg bid dosing regimen. This is an ASCO Meeting Abstract from ...

Receptor Tyrosine Kinases select RTKs) regulate many critical processes such as cell growth, differentiation, and survival through the recruitment of intracellular signaling molecules. Dysregulated ...

University of Toronto scientists have uncovered more than 300 drug targets in cancer, attracting interest from the pharmaceutical industry looking to develop more precise treatments. Led by Professor ...

A new editorial paper was published in Oncotarget, titled "Impact of SHP2 tyrosine phosphorylation on the development of acquired resistance to allosteric SHP2 inhibitors." The SH2 domain-containing ...